Company: LBRX
Filing Date: 2025-08-22
Form Type: S-1
Source: 0001193125-25-186467
Chunk: 306

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-08-22
Form: S-1
Chunk 306
---
 manager to the Master Fund and may be deemed to beneficially own such shares. Deep  
 Track Capital GP, LLC, or the General Partner, is the General Partner of the Investment Manager. David Kroin is the Chief Investment Officer of the Investment Manager and managing member of the General Partner and may be deemed to beneficially own 
 such shares. The business address of the Master Fund, the Investment Manager, the General Partner and Mr. Kroin is 200 Greenwich Avenue, 3rd Floor, Greenwich, CT 06830.                                                                                |

| (2) | Consists of (i) 40,000 shares of common stock held by Vida Ventures Management Co, LLC, (ii) 30,667 shares of                                                                                                                                    
 common stock issuable upon conversion of shares of our redeemable convertible preferred stock held by Vida Ventures III-A, L.P. and (iii) 13,302,666 shares of common stock issuable upon conversion of shares of                                
 our redeemable convertible preferred stock held by Vida Ventures III, L.P. Vida Ventures III-A, L.P. and Vida Ventures III, L.P. are collectively referred to as the “Vida Funds.” Vida Ventures GP                                              
 III, L.L.C., or Vida GP, is the general partner of each of the Vida Funds. Vida Ventures Management Co., LLC is the management company of the Vida Funds. Dr. Jain, a member of our board of directors, is a managing member of Vida GP. Each of 
 Vida GP and Dr. Jain may be deemed to have voting and dispositive power with respect to the shares owned by the Vida Funds. Each of Vida GP and Dr. Jain disclaims beneficial ownership of such shares, except to the extent of their            
 respective pecuniary interests therein. The address for each of these entities and individuals is 10100 Santa Monica Blvd, 15th Floor, Los Angeles, CA 90067.                                                                                    |

| (3) | Consists of (i) 6,362,625 shares of common stock issuable upon conversion of shares of our redeemable                                                                                                                                                     
 convertible preferred stock held by Pontifax (Israel) VI Limited Partnership, or Pontifax Israel, and (ii) 3,637,375 shares of common stock issuable upon conversion of shares of our redeemable convertible preferred stock held by Pontifax (Cayman) VI 
 Limited Partnership, or Pontifax Cayman. Pontifax Israel and Pontifax Cayman are